3
views
0
recommends
+1 Recommend
1 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Tratamiento de pacientes con COVID-19 en Hemodiálisis: Eficacia de Remdesivir Translated title: Treatment of patients with COVID-19 on Hemodialysis: Efficacy of Remdesivir

      letter

      Read this article at

      ScienceOpenPublisherPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Translated abstract

          Background: There is no standard therapy for hemodialysis (HD) patients with COVID-19. Data on remdesivir in HD patients with COVID-19 are scarce.

          Methods: We retrospectively analyzed 25 HD patients with COVID-19 treated with remdesivir.

          Results: The median age of the patients was 78 years (range, 45–92 years) and was predominantly male (84%). A total of 44% of the patients had mild disease, 36% had moderate-1, and 20% had moderate-2. The most common symptoms were fever (76%) and coughing (44%). The most common comorbidity was renal failure (100%), followed by hypertension (60%) and cardiac disease (44%). The most frequent biomarker was elevated creatinine (100%), followed by C-reactive protein (80%), lymphopenia (76%), and D-dimer (68%). C-reactive protein levels decreased significantly before and after remdesivir administration (p < 0.001). Two patients showed deterioration, but none died. All patients recovered from COVID-19 and no adverse effects of treatment with remdesivir were observed.

          Conclusion: Our study suggests the safe use of remdesivir in HD patients with COVID-19.

          Related collections

          Author and article information

          Journal
          Nefrologia
          Nefrologia
          Nefrologia
          Sociedad Española de Nefrología. Published by Elsevier España, S.L.U.
          0211-6995
          1989-2284
          3 August 2022
          3 August 2022
          Affiliations
          [0005]Internal Medicine, Biwako Ohashi Hospital, 5-1-29 Mano, Otsu city, Shiga, 520-0232, Japan
          Author notes
          [* ]Corresponding author: Internal Medicine, Biwako Ohashi Hospital, 5-1-29 Mano, Otsu city, Shiga, 520-0232, Japan
          Article
          S0211-6995(22)00123-0
          10.1016/j.nefro.2022.07.004
          9345654
          9afb0d7a-dba9-4f98-913b-838d7cc2b418
          © 2022 Sociedad Española de Nefrología. Published by Elsevier España, S.L.U.

          Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.

          History
          : 15 June 2022
          Categories
          Letter to the Editor

          covid-19,hemodialysis,remdesivir,treatment,c-reactive protein

          Comments

          Comment on this article